Argen X (Belgium) Executives
| ARGX Stock | EUR 600.40 2.00 0.33% |
Argen X employs about 650 people. The company is managed by 10 executives with a total tenure of roughly 1517 years, averaging almost 151.0 years of service per executive, having 65.0 employees per reported executive. Discussion of Argen X's management performance can provide insight into the enterprise performance.
| Karl Gubitz Insider Chief Officer |
| Beth DelGiacco Insider VP Relations |
Argen |
Argen X Management Team Effectiveness
The company has return on total asset (ROA) of (0.1649) % which means that it has lost $0.1649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3064) %, meaning that it generated substantial loss on money invested by shareholders. Argen X's management efficiency ratios could be used to measure how well Argen X manages its routine affairs as well as how well it operates its assets and liabilities.Argen X Workforce Comparison
Argen X is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 13,026. Argen X holds roughly 650 in number of employees claiming about 5% of equities under Health Care industry.
Argen X Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Argen X Price Series Summation is a cross summation of Argen X price series and its benchmark/peer.
Argen X Notable Stakeholders
An Argen X stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Argen X often face trade-offs trying to please all of them. Argen X's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Argen X's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Karl Gubitz | Chief Officer | Profile | |
| Beth DelGiacco | VP Relations | Profile | |
| Malini Moorthy | G Counsel | Profile | |
| EMBA MBA | CEO Director | Profile | |
| Filip Borgions | VP Operations | Profile | |
| Pr Ir | CoFounder Officer | Profile | |
| Keith Woods | Chief Officer | Profile | |
| Arjen MSc | VP Strategy | Profile | |
| David MD | Advisor | Profile | |
| Andria Wilk | Global Quality | Profile |
About Argen X Management Performance
The success or failure of an entity such as Argen X often depends on how effective the management is. Argen X management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Argen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Argen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. ARGENX SE operates under Pharmaceuticals And Biosciences classification in Belgium and is traded on Brussels Stock Exchange. It employs 650 people.
Argen X Workforce Analysis
Traditionally, organizations such as Argen X use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Argen X within its industry.Argen X Manpower Efficiency
Return on Argen X Manpower
| Revenue Per Employee | 765K | |
| Revenue Per Executive | 49.7M | |
| Net Loss Per Employee | 628.1K | |
| Net Loss Per Executive | 40.8M |
Additional Tools for Argen Stock Analysis
When running Argen X's price analysis, check to measure Argen X's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argen X is operating at the current time. Most of Argen X's value examination focuses on studying past and present price action to predict the probability of Argen X's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argen X's price. Additionally, you may evaluate how the addition of Argen X to your portfolios can decrease your overall portfolio volatility.